Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AVQWJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
BAT8003
|
|||||
| Synonyms |
Anti-Trop-2 ADC; Anti-Trop-2 antibody-drug conjugate; BAT 8003; BAT-8003; BAT8003
Click to Show/Hide
|
|||||
| Organization |
Bio-Thera Solutions, Ltd.
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
3.5
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TROP2)
|
Antigen Info | ||||
| Payload Name |
Maytansinoid derivative of batansine
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
6-Maleimidocaproic acid
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
batansine
|
|||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03884517 | Clinical Status | Phase 1 | ||
| Clinical Description | An open, escalating phase 1 clinical trial of BAT8003 (for injection) on the safety, tolerability and pharmacokinetics for patients with advanced epithelial cancer. | ||||
References